ArticleEuropean journal of nuclear medicine and molecular imaging2017
The accuracy of
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- CanRadiation oncology (London, England) · 2020Pooled it
- PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Pooled it
- The Role ofFrontiers in oncology · 2020Pooled it
- Potential Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Trial
- Molecular Imaging in Photon Radiotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- [Options in nuclear medicine for advanced prostate cancer in practice].Radiologie (Heidelberg, Germany) · 2025Article
- [Options in nuclear medicine for advanced prostate cancer in practice].Urologie (Heidelberg, Germany) · 2025Review
- A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.EJNMMI research · 2025Article
- Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.European radiology · 2024Article
- Comments on Study of "Performance of 18F-DCFPyL PET/CT in Primary Prostate Cancer Diagnosis, Gleason Grading and D'Amico Classification: A Radiomics-Based Study".Phenomics (Cham, Switzerland) · 2023Article
- Performance ofPhenomics (Cham, Switzerland) · 2023Article
- Clinical Significance of Radical Prostatectomy in Clinical Lymph Node Metastasis in Prostate Cancer.Annals of surgical oncology · 2023Article
- Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.International urology and nephrology · 2023Article
- Article
- Evaluation of the role of local therapy in patients with cN1M0 prostate cancer: A population-based study from the SEER database.Frontiers in oncology · 2022Article
- Review
- Comparison ofEuropean urology open science · 2021Review
- Prospective comparison ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
purposeTo assess the diagnostic accuracy of
methodsThis was a multicentre trial of the Society of Urologic Oncology in Turkey in conjunction with the Nuclear Medicine Department of Cerrahpasa School of Medicine, Istanbul University. Patients were accrued from eight centres. Patients with high-risk and very high-risk disease scheduled to undergo surgical treatment with extended LN dissection between July 2014 and October 2015 were included. Either MRI or CT was used for morphological imaging. PSMA PET/CT was performed and evaluated at a single centre. Sensitivity, specificity and accuracy were calculated for the detection of lymphatic metastases by PSMA PET/CT and morphological imaging. Kappa values were calculated to evaluate the correlation between the numbers of LN metastases detected by PSMA PET/CT and by histopathology.
resultsData on 51 eligible patients are presented. The sensitivity, specificity and accuracy of PSMA PET in detecting LN metastases in the primary setting were 53%, 86% and 76%, and increased to 67%, 88% and 81% in the subgroup with of patients with ≥15 LN removed. Kappa values for the correlation between imaging and pathology were 0.41 for PSMA PET and 0.18 for morphological imaging.
conclusionsPSMA PET/CT is superior to morphological imaging for the detection of metastatic LNs in patients with primary prostate cancer. Surgical dissection remains the gold standard for precise lymphatic staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.